![MMAE-[d8]](https://resource.bocsci.com/structure/2070009-72-0.gif)
Inquiry Basket
CAS No.: 1714088-51-3
Cat No.: BADC-01605
4.5 
Telisotuzumab vedotin is a c-Met-targeted antibody and MMAE drug conjugate. Telisotuzumab vedotin has the potential for advanced non-small cell lung cancer treatment.
Structure of 1714088-51-3
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01614 | Glembatumumab vedotin | 1182215-65-1 | |
| BADC-01606 | Polatuzumab vedotin | 1313206-42-6 | |
| BADC-01596 | Enfortumab vedotin-ejfv | 1346452-25-2 | |
| BADC-01610 | Tisotumab vedotin | 1418731-10-8 | |
| BADC-01597 | Ladiratuzumab vedotin | 1629760-29-7 | |
| BADC-01600 | Sirtratumab vedotin | 1824663-83-3 | |
| BADC-01604 | Disitamab vedotin | 2136633-23-1 | |
| BADC-00031 | Brentuximab vedotin | 914088-09-8 | |
| BADC-01613 | Zilovertamab vedotin |
Telisotuzumab vedotin
Required fields are marked with *
Telisotuzumab vedotin
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
